Bharat biotech company, Biotechnology company

Amid the reports of delayed production of its COVID-19 vaccine due to unsatisfactory test batch and quality issues, Hyderabad-based manufacturer Bharat Biotech on Thursday said every batch of Covaxin[?] is subjected to more than 200 quality control tests, followed by submission samples to Central Drugs Laboratory (CDL)."Every batch of Covaxin[?] is subjected to more than 200 quality control tests at our facilities, followed by submission samples to Central Drugs Laboratory (CDL) Government of India, only based on approval/release by CDL, are batches released commercially," read Bharat Biotech's statement.The statement came after reports that test batches of Covaxin from the Bengaluru plant were not satisfactory and got rejected leading to delayed production.Earlier, speaking to ANI, NK Arora, chairperson of the Working Group of the National Technical Advisory Group on Immunisation said, "The test batches of that plant were not satisfactory and got rejected which led to delay in ramping up production, but now the batches have been approved by the competent authority and will be available for public consumption."The Hyderabad-based company said all batches of Covaxin are manufactured and released only from our manufacturing facilities at Genome Valley Hyderabad, which are fully audited and approved by regulatory authorities. Hence we wish to put to rest any concerns on the quality of Covaxin, it said.Giving details of its manufacturing and quality checks, Bharat Biotech said it maintains an uncompromising policy on safety and quality. "Bharat Biotech has not sought Indemnity from the Government of India for any adverse events from Covaxin," [?]the statement added.Bharat Biotech informed that manufacturing of Covaxin[?] commenced at Malur, Karnataka and Ankleshwar, Gujarat, prior to which engineering batches were also executed to study equipment functionality.Products manufactured from these facilities will be available for supplies during September. This is based on the company's 120-day timeline for manufacturing, testing, release, regulatory approvals and distribution," read the release.The vaccine manufacturer said it is the only company to develop a vaccine indigenously in India and manufacture it large scale. "Covaxin is the only vaccine to have demonstrated efficacy against the delta variant in phase III human clinical trials," the statement claimed.The company said fake news and false and misleading narratives result in unintended consequences of creating panic in the country's population resulting in vaccine hesitancy.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Bharat Biotech CompanyFOLLOW

Bharat biotech company, Latest News

The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday. ...

The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain ...

New Delhi, Aug 29 The Union Health Minister Mansukh Mandaviya on Sunday released the first commercial batch of ... ...

Union Minister of Health and Family Welfare, Mansukh Mandaviya on Sunday launched the first commercial batch of Bharat Biotech's COVAXIN manufactured in Gujarat's Ankleshwar. ...

Haryana Home Minister Anil Vij was admitted to the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh after his oxygen level dipped on Sunday. ...

Bharat Biotech on Thursday informed that the Hyderabad- based company has till now supplied 75 million doses of its Covid-19 vaccine Covaxin and more will be supplied this month. ...

Hyderabad, Aug 5 Amid concerns in some quarters about the safety of Covaxin, Bharat Biotech has clarified that ... ...

Amid the reports of delayed production of its COVID-19 vaccine due to unsatisfactory test batch and quality issues, Hyderabad-based manufacturer Bharat Biotech on Thursday said every batch of Covaxin[?] is subjected to more than 200 quality control t ...